These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
857 related articles for article (PubMed ID: 30297397)
1. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). Kowanetz M; Zou W; Gettinger SN; Koeppen H; Kockx M; Schmid P; Kadel EE; Wistuba I; Chaft J; Rizvi NA; Spigel DR; Spira A; Hirsch FR; Cohen V; Smith D; Boyd Z; Miley N; Flynn S; Leveque V; Shames DS; Ballinger M; Mocci S; Shankar G; Funke R; Hampton G; Sandler A; Amler L; Mellman I; Chen DS; Hegde PS Proc Natl Acad Sci U S A; 2018 Oct; 115(43):E10119-E10126. PubMed ID: 30297397 [TBL] [Abstract][Full Text] [Related]
2. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). Peters S; Gettinger S; Johnson ML; Jänne PA; Garassino MC; Christoph D; Toh CK; Rizvi NA; Chaft JE; Carcereny Costa E; Patel JD; Chow LQM; Koczywas M; Ho C; Früh M; van den Heuvel M; Rothenstein J; Reck M; Paz-Ares L; Shepherd FA; Kurata T; Li Z; Qiu J; Kowanetz M; Mocci S; Shankar G; Sandler A; Felip E J Clin Oncol; 2017 Aug; 35(24):2781-2789. PubMed ID: 28609226 [TBL] [Abstract][Full Text] [Related]
3. Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer. Theelen WSME; Kuilman T; Schulze K; Zou W; Krijgsman O; Peters DDGC; Cornelissen S; Monkhorst K; Sarma P; Sumiyoshi T; Amler LC; Willems SM; Blaauwgeers JLG; van Noesel CJM; Peeper DS; van den Heuvel MM; Kowanetz M PLoS One; 2019; 14(5):e0216864. PubMed ID: 31125352 [TBL] [Abstract][Full Text] [Related]
4. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas. Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153 [TBL] [Abstract][Full Text] [Related]
5. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. Horn L; Gettinger SN; Gordon MS; Herbst RS; Gandhi L; Felip E; Sequist LV; Spigel DR; Antonia SJ; Balmanoukian A; Cassier PA; Liu B; Kowanetz M; O'Hear C; Fassò M; Grossman W; Sandler A; Soria JC Eur J Cancer; 2018 Sep; 101():201-209. PubMed ID: 30077125 [TBL] [Abstract][Full Text] [Related]
6. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer. Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072 [TBL] [Abstract][Full Text] [Related]
7. Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab. Vennapusa B; Baker B; Kowanetz M; Boone J; Menzl I; Bruey JM; Fine G; Mariathasan S; McCaffery I; Mocci S; Rost S; Smith D; Dennis E; Tang SY; Damadzadeh B; Walker E; Hegde PS; Williams JA; Koeppen H; Boyd Z Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):92-100. PubMed ID: 29346180 [TBL] [Abstract][Full Text] [Related]
8. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma. Del C Monroig-Bosque P; Driver B; Morales-Rosado JA; Deavers M; Tacha D; Bernicker E; Cagle PT; Miller RA Arch Pathol Lab Med; 2018 Nov; 142(11):1388-1393. PubMed ID: 29431467 [TBL] [Abstract][Full Text] [Related]
9. FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC. Spigel DR; Chaft JE; Gettinger S; Chao BH; Dirix L; Schmid P; Chow LQM; Hicks RJ; Leon L; Fredrickson J; Kowanetz M; Sandler A; Funke R; Rizvi NA J Thorac Oncol; 2018 Nov; 13(11):1733-1742. PubMed ID: 29775807 [TBL] [Abstract][Full Text] [Related]
10. Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study. Boothman AM; Scott M; Ratcliffe M; Whiteley J; Dennis PA; Wadsworth C; Sharpe A; Rizvi NA; Garassino MC; Walker J J Thorac Oncol; 2019 Aug; 14(8):1390-1399. PubMed ID: 31063864 [TBL] [Abstract][Full Text] [Related]
11. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion. Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552 [TBL] [Abstract][Full Text] [Related]
12. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8 Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272 [TBL] [Abstract][Full Text] [Related]
13. Hu B; Chen W; Zhang Y; Shi H; Cheng D; Xiu Y Ann Nucl Med; 2020 May; 34(5):322-328. PubMed ID: 32130663 [TBL] [Abstract][Full Text] [Related]
14. Atezolizumab for the treatment of non-small cell lung cancer. Santini FC; Rudin CM Expert Rev Clin Pharmacol; 2017 Sep; 10(9):935-945. PubMed ID: 28714780 [TBL] [Abstract][Full Text] [Related]
15. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy. Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH Front Immunol; 2021; 12():654463. PubMed ID: 34054817 [TBL] [Abstract][Full Text] [Related]
16. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372 [TBL] [Abstract][Full Text] [Related]
17. Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung. Kim HS; Lee JH; Nam SJ; Ock CY; Moon JW; Yoo CW; Lee GK; Han JY J Thorac Oncol; 2018 May; 13(5):636-648. PubMed ID: 29378266 [TBL] [Abstract][Full Text] [Related]
18. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201 [TBL] [Abstract][Full Text] [Related]
20. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]